Second-Generation Antipsychotic Monotherapy Contributes to the Discontinuation of Anticholinergic Drugs in Hospitalized Patients with Schizophrenia

  • Tsuyoshi Okada
  • , Hikaru Hori
  • , Naomi Hasegawa
  • , Atsunobu Murata
  • , Yoshitaka Kyou
  • , Fumitoshi Kodaka
  • , Hitoshi Iida
  • , Shinichiro Ochi
  • , Yoshikazu Takaesu
  • , Takashi Tsuboi
  • , Jun Ichi Iga
  • , Kayo Ichihashi
  • , Hiroyuki Muraoka
  • , Ryuji Furihata
  • , Norio Yasui-Furukori
  • , Masahide Usami
  • , Toshiaki Onitsuka
  • , Kazuyoshi Ogasawara
  • , Hiromi Tagata
  • , Masahiro Takeshima
  • Kazutaka Ohi, Shusuke Numata, Naoki Hashimoto, Hiroki Yamada, Manabu Makinodan, Hiroshi Komatsu, Akitoyo Hishimoto, Hirotaka Yamagata, Mikio Kido, Chika Kubota, Kiyokazu Atake, Hisashi Yamada, Tatsuya Nagasawa, Junya Matsumoto, Kenichiro Miura, Ken Inada, Koichiro Watanabe, Shiro Suda, Ryota Hashimoto

Research output: Contribution to journalLetterpeer-review

Original languageEnglish
Pages (from-to)591-593
Number of pages3
JournalJournal of Clinical Psychopharmacology
Volume42
Issue number6
DOIs
Publication statusPublished - 01-11-2022
Externally publishedYes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

All Science Journal Classification (ASJC) codes

  • Psychiatry and Mental health
  • Pharmacology (medical)

Cite this